Edoc Acquisition Corp. Class A Ordinary Share (ADOC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADOC Stock Price Chart Interactive Chart >
ADOC Price/Volume Stats
| Current price | $10.39 | 52-week high | $11.60 |
| Prev. close | $10.40 | 52-week low | $10.00 |
| Day low | $10.39 | Volume | 5,900 |
| Day high | $10.40 | Avg. volume | 27,568 |
| 50-day MA | $10.31 | Dividend yield | N/A |
| 200-day MA | $10.21 | Market Cap | 50.19M |
Latest ADOC News From Around the Web
Below are the latest news stories about EDOC ACQUISITION CORP that investors may wish to consider to help them evaluate ADOC as an investment opportunity.
EDOC Acquisition Corp. Announces Voting Results of Extraordinary General Meeting to Approve the Extension AmendmentNew York, NY, Aug. 15, 2022 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (Nasdaq: ADOC, ADOCR, ADOCW, “EDOC” or the “Company”), a special purpose acquisition company, announced today that the Company’s shareholders voted in favor of the proposal to amend its charter (the “Extension Amendment”) to extend the date by which the Company has to complete a business combination from August 12, 2022 to February 12, 2023 (the “Extension”), at the extraordinary general meeting of EDOC shareholders that took |
Edoc Acquisition Corp. Announces Termination of Merger Agreement with Calidi Biotherapeutics, Inc.New York, NY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp. (Nasdaq: ADOC, ADOCR, ADOCW, “EDOC” or the “Company”), a special purpose acquisition company, announced today the termination of its previously announced agreement and plan of merger (the “Merger Agreement”) with Calidi Biotherapeutics, Inc. (“Calidi”). Although Edoc and Calidi may continue to discuss the possibility of engaging in a business combination, there can be no assurance that those discussions will result in a trans |
Edoc Acquisition Corp. Announce Postponement of Special Meeting of Shareholders to Extend the Deadline to Consummate an Initial Business Combination● Extraordinary General Meeting of Edoc’s shareholders postponed until August 12, 2022, at 8:00 p.m., Eastern Time NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp. (Nasdaq: ADOC, ADOCR, ADOCW, “EDOC” or the “Company”), today announced the postponement of Edoc’s extraordinary general meeting of shareholders (the “Special Meeting”) originally scheduled to be held on August 12, 2022 at 10:00 am Eastern Time. The Special Meeting has been postponed until August 12, 2022 at 8:00 p.m. |
Edoc Acquisition Corp. Reminds Shareholders to Vote and Announces Additional Contribution for Extension AmendmentNEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp. (Nasdaq: ADOC, ADOCR, ADOCW, “EDOC” or the “Company”) encourages its shareholders to vote in favor of the proposal to amend its charter (the “Extension Amendment”) to extend the date by which the Company has to complete a business combination from August 12, 2022 to February 12, 2023 (the “Extension”). An extraordinary general meeting of the Company’s shareholders (“Special Meeting”) to approve the Extension Amendment will be hel |
ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua DongbaoLYON, France, April 11, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the final approval by the German (BfArM) regulatory authorities to conduct three clinical studies on BioChaperone® Combo ("BC Combo"). |
ADOC Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 1.96% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2021 | 0.00% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...